What changed, and when

Samsung Bioepis and Epis NexLab announced a research collaboration and license agreement with G2GBIO on 16 Mar 2026 to develop novel sustained-release assets, led by a long-acting semaglutide (Business Wire). Under the terms, Samsung Bioepis acquires exclusive global rights for development and commercialization of the assets, while parent entity Samsung Epis Holdings invests 20 billion KRW (approximately $13.3 million) in G2GBIO convertible bonds (Korea Biomedical Review).

60-second thesis frame

This deal marks the first major strategic pivot for Samsung Bioepis following its Nov 2025 spin-off into Samsung Epis Holdings, signaling an aggressive move from “pure-play” biosimilars into the high-margin “bio-better” and novel biologics space (SynBioBeta, Goodwin). By leveraging G2GBIO’s InnoLamp microsphere technology, Samsung aims to disrupt the weekly GLP-1 dominance of Novo Nordisk and Eli Lilly with a monthly (or quarterly) injectable that promises more stable pharmacokinetic (PK) profiles and reduced injection site reactions (G2GBIO Technology). While the GLP-1 market is projected to reach $74.4 billion in 2026, competition is intensifying from oral formulations and other long-acting antibodies like Amgen’s MariTide (Persistence Market Research, Visiongain). Samsung’s core advantage lies in its industrial-scale manufacturing capability, which may solve the historical scalability and uniformity issues inherent in microsphere production (The Pharmaletter).

The seven diligence questions

Clinical

• Does the InnoLamp platform successfully suppress the “initial burst” of semaglutide in human subjects to avoid severe gastrointestinal (GI) side effects? (Google Patents)
• What is the specific weight-loss efficacy of GB-7001 (the monthly candidate) compared to the 14.9% mean reduction seen in weekly 2.4mg Wegovy? (Persistence Market Research)

Payer or Access

• Will US payers (Medicare/Medicaid) grant a price premium for monthly “convenience” dosing, or will the drug be tiered as a bio-better competing primarily on net price? (J.P. Morgan)
• How will the CMS BALANCE pilot program, targeting $50 monthly out-of-pocket caps, impact the commercial viability of a novel long-acting injectable? (J.P. Morgan)

Ops or Adoption

• Can Samsung’s manufacturing facilities maintain the strict particle-size uniformity required for reliable 28-day release at the volumes needed for global obesity markets? (Samsung Biologics News)

Competitive

• How does Samsung’s monthly semaglutide differentiate against Amgen’s MariTide (GIPR/GLP-1R antibody) which is also designed for monthly dosing? (Visiongain)

Team or Cap table

• Following the 2025 reorganization, does Samsung Bioepis have the internal clinical development infrastructure to manage a novel global Phase 3 program, or will it remain reliant on Epis NexLab for R&D? (Samsung Bioepis 2025 Review)

Red flags

• Microsphere Inflammation: Historical long-acting microsphere injectables have faced significant clinical delays due to granulomas or injection site reactions. (G2GBIO News)
• Oral Disruption: The launch of daily oral GLP-1s in early 2026 may shift patient preference away from any injectable, regardless of dosing frequency (monthly vs. weekly). (J.P. Morgan)
• Manufacturing Scalability: G2GBIO’s InnoLamp tech has shown success in 10–20 kg pilot batches, but scaling to hundreds of metric tons for global obesity demand is unproven for microspheres. (G2GBIO Overview)

Next catalyst

Completion of G2GBIO’s second GMP manufacturing facility in late 2026 to support global clinical supply. (Korea Biomedical Review)

FAQ

• What exactly changed by Samsung Bioepis’s “research collaboration and license agreement” news on 16 Mar 2026, and why does it matter for the obesity market?
  Samsung Bioepis partnered with G2GBIO to develop a long-acting (monthly) version of semaglutide, acquiring exclusive global rights (Business Wire). This is significant because it represents Samsung’s first major entry into “novel” drug development, moving beyond its traditional biosimilar business to compete with industry leaders like Novo Nordisk.
• What is the regulatory path after the agreement between Samsung Bioepis and G2GBIO, and what are the next formal steps?
  The assets are moving into global clinical development, with Samsung Bioepis managing the regulatory filings with the FDA, EMA, and MHRA (The Pharmaletter). The immediate next step is the commencement of advanced clinical trials (Phase 2/3) to confirm the 28-day release profile in humans (Korea Biomedical Review).
• Which technology drove the results cited in the 16 Mar 2026 news about Samsung Bioepis and G2GBIO?
  The agreement centers on G2GBIO’s InnoLamp (Innovative Long-Acting Microsphere Platform) technology, which encapsulates drugs in biodegradable microspheres (G2GBIO Website). Non-clinical data previously demonstrated consistent semaglutide concentration in the bloodstream for over 28 days without a sharp “initial burst” of medication (G2GBIO News).
• What safety issues matter for long-acting semaglutide, and do they change real-world use?
  Sustained-release formulations must avoid “dose dumping” (releasing too much drug at once), which can cause severe nausea and vomiting (Google Patents). Additionally, microspheres must be optimized to prevent inflammation or lumps at the subcutaneous injection site to ensure patient adherence (G2GBIO News).
• How will major US payers treat access to a monthly semaglutide?
  Payers may favor monthly dosing if clinical data proves better patient adherence, potentially reducing overall healthcare costs (J.P. Morgan). However, it will face intense competition from Medicare-negotiated prices for weekly brands and more affordable oral GLP-1 alternatives launched in 2026 (J.P. Morgan, The Pharmaletter).

Publisher / Disclosure

Publisher: LucidQuest Ventures Ltd. Produced: 16 Mar 2026, 20:15 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.

Entities / Keywords

Samsung Bioepis; G2GBIO; Epis NexLab; Samsung Epis Holdings; Samsung Biologics; semaglutide; GLP-1 receptor agonist; obesity; type 2 diabetes; InnoLamp; microsphere; sustained-release; long-acting injectable; GB-7001; weight management; biosimilar; bio-better; drug delivery; Kyung-Ah Kim; Lee Hee-yong; South Korea; Incheon; FDA; EMA; Medicare; CMS; BALANCE program; Amgen; MariTide; clinical trials; GMP facility.

 

Find more Lucid Diligence Briefs here.